Regeneron Pharmaceuticals and Sanofi are conducting a Phase 3 clinical study titled A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Invest ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Sanofi, Regeneron eye $11B in Dupixent sales with ... The move will cause "no change" to their ongoing partnership, the companies said. Sanofi will retain about 400,000 shares in Regeneron stock ...

NEW YORK, Nov 10 (Reuters) - Regeneron Pharmaceuticals Inc and French drugmaker Sanofi-aventis said on Tuesday they have expanded their partnership to develop a number of Regeneron's experimental ...

Sanofi and Regeneron rejiggered their longstanding antibody ... The move will cause "no change" to their ongoing partnership, the companies said. Sanofi will retain around 400,000 shares in ...

U.S. drugmaker Regeneron Pharmaceuticals said on Monday it would repurchase about $5 billion of its shares directly from France's Sanofi, without altering their over-a-decade-long partnership.

Sanofi recognizes all revenue from antibodies in the partnership. The drug accounted for €10.7 billion (about $11.6 billion) in sales in 2023, up nearly 30% from the prior year, according to the ...

Sanofi, Regeneron begin testing coronavirus treatment with arthritis drug The announcement came as global confirmed cases of COVID-19, the disease caused by the novel coronavirus, neared 175,000 ...

But Sanofi has begun to talk up its internal efforts and step back from key partnerships, most notably with Regeneron. Cancer immuno-oncology multiple myeloma partnerships EuroBiotech Report ...

Sanofi’s R&D site in Vitry-Sur-Seine, near Paris. Sanofi and Regeneron said that drug candidate Itepekimab didn’t hit the main objective of a second trial.

French drugmaker Sanofi SA <SASY.PA> is buying more shares in U.S. biotech company Regeneron Pharmaceuticals Inc <REGN.O>, its partner in the development of potential blockbuster treatments for ...